A potential role of chondroitin sulfatfrancise on bone in osteoarthritis: Inhibition of prostaglandin E 2 and matrix metalloproteinases synthesis in interleukin-1β- stimulated osteoblasts

Osteoarthritis and Cartilage

Volumn 20, Issue 2, 2012, Pages 127-135

  Pecchi, E ^a   Priam, S ^a   Mladenovic, Z ^a   Gosset, M ^a   Saurel, A S ^c   Aguilar, L ^c   Berenbaum, F ^a,b   Jacques, C ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Chondroitin sulfate; MMPs; Osteoarthritis; Osteoblasts; PGE2

Indexed keywords

CHONDROITIN SULFATE; COLLAGENASE 3; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; STROMELYSIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INCUBATION TEMPERATURE; MOUSE; NONHUMAN; OSTEOARTHRITIS; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CELLS, CULTURED; CHONDROITIN SULFATES; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTRAMOLECULAR OXIDOREDUCTASES; MATRIX METALLOPROTEINASES; MICE; OSTEOBLASTS; OSTEOPROTEGERIN; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84855852951     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2011.12.002     Document Type: Article

References (56)

1. Bijlsma J., Berenbaum F., Lafeber F. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011, 377(9783):2115-2126.
2. Martel-Pelletier J., Lajeunesse D., Reboul P., Pelletier J.P. The role of subchondral bone in osteoarthritis. Osteoarthritis: A Companion to Rheumatology 2007, 15-32. Mosby Elsevier, Philadelphia. L. Sharma, F. Berenbaum (Eds.).
3. Garstang S.V., Stitik T.P. Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil 2006, 85. S2-11.
4. Goldring M.B., Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 2004, (427 Suppl):S37-S46. Review.
5. Aigner T., Sachse A., Gebhard P.M., Roach H.I. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev 2006, 58(2):128-149.
6. Miyaura C., Inada M., Suzawa T., Sugimoto Y., Ushikubi F., Ichikawa A., et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. JBiol Chem 2000, 275:19819-19823.
7. Trebino C.E., Stock J.L., Gibbons C.P., Naiman B.M., Wachtmann T.S., Umland J.P., et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 2003, 100(15):9044-9049.
8. Masuko-Hongo K., Berenbaum F., Humbert L., Salvat C., Goldring M.B., Thirion S. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum 2004, 50(9):2829-2838.
9. Tai H.H., Cho H., Tong M., Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 2006, 12(8):955-962.
10. Gosset M., Berenbaum F., Levy A., Pigenet A., Thirion S., Saffar J.L., et al. Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a mechanosensitive gene. Arthritis Res Ther 2006, 8(4):R135.
11. Sanchez C., Gabay O., Salvat C., Henrotin Y.E., Berenbaum F. Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis Cartilage 2009, 17(4):473-481.
12. Burrage P.S., Mix K.S., Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543.
13. Kusano K., Miyaura C., Inada M., Tamura T., Ito A., Nagase H., et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and-13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 2008, 139:1338-1345.
14. Inada M., Wang Y., Byrne M.H., Rahman M.U., Miyaura C., López-Otín C., et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci U S A 2004, 101:17192-17197.
15. Kwan Tat S., Pelletier J.P., Lajeunesse D., Fahmi H., Lavigne M., Martel-Pelletier J. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008, 26(2):295-304.
16. The'oleyre T., Wittrant Y., Kwan Tat S., Fortun Y., Re'dini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15:457-475.
17. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
18. Taylor K.R., Gallo R.L. Glycosaminoglycans and their proteoglycans: host associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006, 20:9-22.
19. Dudhia J. Aggrecan, aging and assembly in articular cartilage. Cell Mol Life Sci 2005, 62:2241-2256.
20. Uebelhart D., Malaise M., Marcolongo R., DeVathaire F., Piperno M., Mailleux E., et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004, 12:269-276.
21. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 2008, 67:735-740.
22. Cool S.M., Nurcombe V. The osteoblast-heparan axis: control of the bone cell lineage. Int J Biochem Cell Biol 2005, 37:1739-1745.
23. Bastow E.R., Byers S., Golub S.B., Clarkin C.E., Pitsillides A.A., Fosang A.J. Hyaluronan synthesis and degradation in cartilage and bone. Cell Mol Life Sci 2008, 65:395-413.
24. Iovu M., Dumais G., du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 2008, 16:14-18.
25. Tat S.K., Pelletier J.P., Vergés J., Lajeunesse D., Montell E., Fahmi H., et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007, 9:R117.
26. Blaise R., Mahjoub M., Salvat C., Barbe U., Brou C., Corvol M.T., et al. Arthritis Rheum 2009, 60(2):428-439.
27. Seibel M.J., Duncan A., Robins S.P. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. JRheumatol 1989, 16:964-970.
28. Sowers M., Zobel D., Weissfeld L., Hawthorne V.M., Carman W. Progression of osteoarthritis of the hand and metacarpal bone loss. A twenty-year followup of incident cases. Arthritis Rheum 1991, 34:36-42.
29. Li B., Marshall D., Roe M., Aspden R.M. The electron microscope appearance of the subchondral bone plate in the human femoral head in osteoarthritis and osteoporosis. JAnat 1999, 195:101-110.
30. Lories R.J., Luyten F.P. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol 2010, 7:43-49.
31. Lamour V., Detry C., Sanchez C., Henrotin Y., Castronovo V., Bellahcene A. Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. JBiol Chem 2007, 282:36240-36249.
32. Martel-Pelletier J., Kwan Tat S., Pelletier J.P. Effects of chondroitin sulfate in the pathophysiology of osteoarthritic joint: a narrative review. Osteoarthritis Cartilage 2010, 18. S7-11.
33. Conte A., de Bernardi M., Palmieri L., Lualdi P., Mautone G., Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung 1991, 41:768-772.
34. Conte A., Palmieri L., Segnini D., Ronca G. Metabolic fate of partially depolymerized chondroitin sulfate administered to the rat. Drugs Exp Clin Res 1991, 17:27-33.
35. Palmieri L., Conte A., Giovannini L., Lualdi P., Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimittelforschung 1990, 40:319-323.
36. Wildi L.M., Raynauld J.P., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011, 70(6):982-989.
37. Hikiji H., Takato T., Shimizu T., Ishii S. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog Lipid Res 2008, 47:107-126.
38. Hilal G., Massicotte F., Martel-Pelletier J., Fernandes J.C., Pelletier J.P., Lajeunesse D. Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts. JBone Miner Res 2001, 16(4):713-721.
39. Lajeunesse D. The role of bone in the treatment of osteoarthritis. Osteoarthritis Cartilage 2004, 12(Suppl A):S34-S38. Review.
40. Kirker-Head C.A., Chandna V.K., Agarwal R.K., Morris E.A., Tidewell A., O'Callaghan M.W., et al. Concentrations of substance P and prostaglandin E2 in synovial fluid of normal and abnormal joints of horses. Am J Vet Res 2000, 61:714-718.
41. Yamada H., Kikuchi T., Nemoto O., Obata K., Sato H., Seiki M., et al. Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by human articular chondrocytes. JRheumatol 1996, 23:1739-1743.
42. 2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 2006, 119:229-240.
43. Kunze R., Hempel U., Dieter P. Differential effect of chondroitin-4-sulfate on the immediate and delayed prostaglandin E2 release from osteoblasts. Prostaglandins Other Lipid Mediat 2010, 92(1-4):8-12.
44. Douglas T., Heinemann S., Mietrach C., Hempel U., Bierbaum S., Scharnweber D., et al. Interactions of collagen types I and II with chondroitin sulfates A-C and their effect on osteoblast adhesion. Biomacromolecules 2007, 8:1085-1092.
45. Ponik S.M., Pavalko F.M. Formation of focal adhesions on fibronectin promotes fluid shear stress induction of COX-2 and PGE2 release in MC3T3-E1 osteoblasts. JAppl Phys 2004, 97:135-142.
46. Legendre F., Baugé C., Roche R., Saurel A.S., Pujol J.P. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1beta-stimulated chondrocytes-study in hypoxic alginate bead cultures. Osteoarthritis Cartilage 2008, 16:105-114.
47. Helfrich M.H., Nesbitt S.A., Lakkakorpi P.T., Barnes M.J., Bodary S.C., Shankar G., et al. Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption. Bone 1996, 19:317-328.
48. Holliday L.S., Welgus H.G., Fliszar C.J., Veith G.M., Jeffrey J.J., Gluck S.L. Initiation of osteoclast bone resorption by interstitial collagenase. JBiol Chem 1997, 272:22053-22058.
49. Shibakawa A., Yudoh K., Masuko-Hongo K., Kato T., Nishioka K., Nakamura H. The role of subchondral bone resorption pits in osteoarthritis: MMP production by cells derived from bone marrow. Osteoarthritis Cartilage 2005, 13(8):679-687.
50. Theoleyre S., Kwan Tat S., Vusio P., Blanchard F., Gallagher J., Ricard-Blum S., et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006, 347:460-467.
51. Itonaga I., Sabokbar A., Sun S.G., Kudo O., Danks L., Ferguson D., et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 2004, 34:57-64.
52. Ramsden L., Rider C.C. Selective and differential binding of interleukin (IL-)-1a, IL1β, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992, 22:3027-3031.
53. Sobal G., Sinzinger H. Binding of [99mTc]chondroitin sulfate to scavenger receptors on human chondrocytes as compared to binding of oxidized [125I]LDL on human macrophages. JRecept Signal Transduct Res 2002, 22:459-470.
54. Kawashima H., Hirose M., Hirose J., Nagakubo D., Plaas A.H., Miyasaka M. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. JBiol Chem 2000, 275:35448-35456.
55. Suwan K., Choocheep K., Hatano S., Kongtawelert P., Kimata K., Watanabe H. Versican/PG-M assembles hyaluronan into extracellular matrix and inhibits CD44-mediated signaling toward premature senescence in embryonic fibroblasts. JBiol Chem 2009, 284:8596-8604.
56. Ajisaka K., Agawa S., Nagumo S., Kurato K., Yokoyama T., Arai K., et al. Evaluation and comparison of the antioxidative potency of various carbohydrates using different methods. JAgric Food Chem 2009, 57:3102-3107.